Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect

@article{Pioro2010DextromethorphanPU,
  title={Dextromethorphan Plus Ultra Low‐Dose Quinidine Reduces Pseudobulbar Affect},
  author={E. Pioro and B. Brooks and J. Cummings and R. Schiffer and R. Thisted and D. Wynn and A. Hepner and R. Kaye},
  journal={Annals of Neurology},
  year={2010},
  volume={68}
}
  • E. Pioro, B. Brooks, +5 authors R. Kaye
  • Published 2010
  • Medicine
  • Annals of Neurology
  • To evaluate dextromethorphan combined with ultra low‐dose quinidine (DMq) for treating pseudobulbar affect (PBA) in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). 
    143 Citations

    Paper Mentions

    Interventional Clinical Trial
    The primary objective of this study is to test the hypothesis that Nuedexta (20/10) administered orally will reduce Pseudobulbar Affect (PBA) frequency and severity (CNS-Lability… Expand
    ConditionsAlzheimer's Disease, Pseudobulbar Affect (PBA)
    InterventionDrug
    Interventional Clinical Trial
    Objectives of the study are to evaluate the safety, tolerability, and efficacy of two different doses of AVP-923 (capsules containing either 30 mg of dextromethorphan hydrobromide… Expand
    ConditionsPseudobulbar Affect (PBA)
    InterventionDrug
    Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial
    • 2
    • Highly Influenced
    Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM‐II Open Label Study
    • 7
    • Highly Influenced
    • PDF
    Pharmacotherapeutic management of pseudobulbar affect.
    • J. Chen
    • Medicine
    • The American journal of managed care
    • 2017
    • 3
    • PDF
    Dextromethorphan/Quinidine: A Review of Its Use in Adults with Pseudobulbar Affect
    • 23
    • Highly Influenced
    Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    • 6
    Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA®) for Pseudobulbar Affect
    • E. Pioro
    • Medicine
    • Neurology and Therapy
    • 2014
    • 21
    • PDF

    References

    SHOWING 1-10 OF 43 REFERENCES
    Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis
    • 151
    Dextromethorphan: Enhancing its systemic availability by way of low‐dose quinidine‐mediated inhibition of cytochrome P4502D6
    • 91
    • Highly Influential
    Sertraline in stroke‐associated lability of mood
    • 108
    Review of pseudobulbar affect including a novel and potential therapy.
    • 105
    • PDF
    Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity
    • D. Choi
    • Chemistry, Medicine
    • Brain Research
    • 1987
    • 166
    Pathologic laughing and crying treated with levodopa.
    • 132
    Treatment of pathologic laughing and weeping with amitriptyline.
    • 180
    Fluoxetine improves emotional incontinence.
    • 89